SCHEMBL2025938

SCHEMBL2025938

O=C(O)N1CCC(c2nc(-c3ccc(F)cc3)no2)CC1

nearest known ligand 0.72

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
LMNA P02545 4/20 0.72
TSHR P16473 4/20 0.72
ALOX15 P16050 1/20 0.72
MAPK1 P28482 1/20 0.72
SMN1; SMN2 Q16637 4/20 0.69
ALDH1A1 P00352 1/20 0.69
TUBB4A P04350 2/20 0.69
TUBB P07437 2/20 0.69
TUBA3C P0DPH7 2/20 0.69
TUBA1B P68363 2/20 0.69
TUBA4A P68366 2/20 0.69
TUBB4B P68371 2/20 0.69
TUBB3 Q13509 2/20 0.69
TUBB2A Q13885 2/20 0.69
TUBB8 Q3ZCM7 2/20 0.69
TUBA3E Q6PEY2 2/20 0.69
TUBA1A Q71U36 2/20 0.69
TUBA1C Q9BQE3 2/20 0.69
TUBB6 Q9BUF5 2/20 0.69
TUBB2B Q9BVA1 2/20 0.69

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6386469 0.89 TUBB4A (0.67) LMNATSHRALOX15MAPK1SMN1; SMN2
SCHEMBL3241112 0.88 TUBB4A (0.69) LMNATSHRALOX15MAPK1SMN1; SMN2
SCHEMBL2027525 0.87 LMNA (0.66) LMNATSHRALOX15MAPK1SMN1; SMN2
SCHEMBL4513166 0.86 SMN1; SMN2 (0.73) LMNATSHRALOX15MAPK1SMN1; SMN2
SCHEMBL25172097 0.84 ALDH1A1 (0.62) LMNATSHRALOX15MAPK1SMN1; SMN2
SCHEMBL2028783 0.84 SMN1; SMN2 (0.55) LMNATSHRALOX15MAPK1SMN1; SMN2
SCHEMBL2029440 0.83 LMNA (0.53) LMNATSHRALOX15MAPK1SMN1; SMN2
SCHEMBL4420449 0.83 LMNA (0.61) LMNATSHRALOX15MAPK1SMN1; SMN2
SCHEMBL32676771 0.82 SMN1; SMN2 (0.53) LMNATSHRALOX15MAPK1SMN1; SMN2
SCHEMBL20116117 0.81 LMNA (0.72) LMNATSHRALOX15MAPK1SMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20110136823-A1 COMPOUNDS HAVING A POTENTIATING EFFECT ON THE ACTIVITY OF ETHIONAMIDE AND USES THEREOF INSTITUT PASTEUR DE LILLE (FR) 2011-06-09 US claimed
US-20260048047-A1 SMALL-MOLECULE ACTIVATORS OF MYCOBACTERIUM TUBERCULOSIS ADENYLYL CYCLASE SCRIPPS RESEARCH INST (US) 2026-02-19 US disclosed
WO-2024030121-A1 SMALL-MOLECULE ACTIVATORS OF MYCOBACTERIUM TUBERCULOSIS ADENYLYL CYCLASE THE SCRIPPS RESEARCH INSTITUTE (US) 2024-02-08 WO disclosed
US-8338599-B2 Compounds having a potentiating effect on the activity of ethionamide and uses thereof INSTITUT PASTEUR DE LILLE (FR) 2012-12-25 US disclosed
US-20110136823-A1 COMPOUNDS HAVING A POTENTIATING EFFECT ON THE ACTIVITY OF ETHIONAMIDE AND USES THEREOF INSTITUT PASTEUR DE LILLE (FR) 2011-06-09 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110136823-A1 COMPOUNDS HAVING A POTENTIATING EFFECT ON THE ACTIVITY OF ETHIONAMIDE AND USES THEREOF EPX, PGLS, ENPEP LMNA 1439/4885TSHR 2305/4885ALOX15 648/4885
US-20260048047-A1 SMALL-MOLECULE ACTIVATORS OF MYCOBACTERIUM TUBERCULOSIS ADENYLYL CYCLASE FNTB, PDE7A, TBL3 LMNA 1838/4885TSHR 620/4885ALOX15 2647/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.